Trainings and Resources
13 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/28/2021 (updated 9/14/2022)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
On March 16, 2020, to facilitate access to methadone treatment from opioid treatment programs (OTPs) during the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration allowed states to request blanket exceptions to provide up to 28 and 14 days of take-home methadone for stable and less stable patients, respectively; this signaled a shift in practice because most patients historically receive methadone daily from OTPs.
Posted 11/25/2020 (updated 7/11/2022)
Jails and prisons are critical intervention points in addressing the nation’s overdose crisis. Many systems, including correctional facilities, are beginning to recognize that access to evidence-based treatment and medication for substance use disorder saves lives and must form a fundamental component of any effective program. This Virtual Event Series will highlight best practices, challenges and opportunities in implementing medication-based treatment in correctional facilities over four sessions.
The goal of treatment for opioid addiction or opioid use disorder (OUD) is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential.1 This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
Posted 3/9/2022 (updated 3/8/2022)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually, yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or buprenorphine) is unknown. OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD in US jails.
Posted 8/11/2021 (updated 9/2/2021)
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) contracted with RTI International to conduct a scoping review of the scientific literature on non-fatal opioidinvolved overdose (NFOO) to better understand the health outcomes and health care implications associated with opioid epidemic. NFOO is a significant cause of opioid-related morbidity in the United States, and is of heightened interest to ASPE given the sharp increase in fatal and nonfatal opioid overdoses as a result of the current fentanyl crisis. Compared to the first and second phases of the opioid epidemic, when the majority of opioid-related morbidity and mortality was associated first with prescription opioids and then with heroin, illicitly-manufactured fentanyl (IMF) is now the leading cause of fatal opioid overdoses (CDC, 2017; O’Donnell, Gladden, & Seth, 2017). People who consume IMF, either wittingly or unwittingly, are at higher risk for accidental overdose, experience comparatively atypical overdose-related side effects, have unique risk profiles, and are at higher risk for poorer health outcomes (Somerville, 2017). To our knowledge, no investigation has been conducted to examine whether the sharp increase in NFOOs over the last several decades is negatively impacting overdose victims’ chronic physical and mental health outcomes. To investigate the status of the scientific literature regarding the consequences of NFOO on victims’ physical and mental health, we conducted a scoping review of the existing knowledge in multiple stages: (1) publication identification; (2) selection of publications; and (3) data extraction, charting, and synthesis. Key findings from our review are presented below.
Posted 4/21/2021 (updated 9/2/2021)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 9/2/2021)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/30/2021 (updated 9/2/2021)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 1/5/2021 (updated 9/2/2021)
This resource is a State Health official letter issued by the Center for Medicaid providing guidance on implementation throughout the Medicaid program of the provision pursuant to Section 1006(b) of the Support for Patients and Communities Act. Within the scope of the SUPPORT Act provision, state Medicaid programs are now required to provide and cover medication-assisted treatment (MAT) and behavioral therapy for opioid use disorders.